Daclizumab was authorised in 2016, following consideration of clinical trial data from 2236 exposed patients. Elevated liver enzymes were common, and there was one death due to autoimmune hepatitis, but no cases of encephalitis were identified in any studies. 2 Post-marketing surveillance, however, has critically swung the risk-benefit balance in favour of product withdrawal.
Despite risk minimisation approaches, a further case of fatal autoimmune hepatitis was reported to the journals.sagepub.com/home/msj Visit SAGE journals online journals.sagepub.com/ home/msj SAGE journals EMA pharmacovigilance committee in June 2017, resulting in a licencing restriction to those who have tried two previous disease-modifying therapies and are unsuitable for any others. 3 In March 2018, however, the EMA recommended the immediate suspension of daclizumab following 12 reports of meningoencephalitis, 3 of which were fatal. 4 The report by Devlin et al. of such a case of immunemediated encephalitis provides a fascinating insight into the complexity of immune modification in MS. It should also serve as a reminder to all of those prescribing disease modifying therapies as to the importance of their duty to report adverse events as they arise.
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